209 related articles for article (PubMed ID: 31328328)
21. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands.
Zomerdijk IM; Ruiter R; Houweling LM; Herings RM; Sturkenboom MC; Straus SM; Stricker BH
BMJ Open; 2014 Nov; 4(11):e005602. PubMed ID: 25392022
[TBL] [Abstract][Full Text] [Related]
22. Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden.
Ankarfeldt MZ; Petersen J; Andersen JT; Li H; Motsko SP; Fast T; Hede SM; Jimenez-Solem E
PLoS Med; 2021 Nov; 18(11):e1003851. PubMed ID: 34807906
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin.
Yook JH; Han JY; Choi JS; Ahn HK; Lee SW; Kim MY; Ryu HM; Nava-Ocampo AA
Clin Toxicol (Phila); 2012 Dec; 50(10):896-901. PubMed ID: 23116253
[TBL] [Abstract][Full Text] [Related]
24. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.
Henry D; Dormuth C; Winquist B; Carney G; Bugden S; Teare G; Lévesque LE; Bérard A; Paterson JM; Platt RW;
CMAJ; 2016 Jul; 188(10):723-730. PubMed ID: 27114489
[TBL] [Abstract][Full Text] [Related]
25. Continued occurrence of Accutane-exposed pregnancies.
Honein MA; Paulozzi LJ; Erickson JD
Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
[TBL] [Abstract][Full Text] [Related]
26. Isotretinoin and pregnancy.
Stern RS; Rosa F; Baum C
J Am Acad Dermatol; 1984 May; 10(5 Pt 1):851-4. PubMed ID: 6233342
[TBL] [Abstract][Full Text] [Related]
27. Nitrosatable drug exposure during pregnancy and risk of stillbirth.
Thomsen AML; Liew Z; Riis AH; Stayner LT; Ramlau-Hansen CH; Sigsgaard T; Olsen J
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1204-1210. PubMed ID: 31348585
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
[TBL] [Abstract][Full Text] [Related]
29. A pregnancy-prevention program in women of childbearing age receiving isotretinoin.
Mitchell AA; Van Bennekom CM; Louik C
N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
Coppola D; Russo LJ; Kwarta RF; Varughese R; Schmider J
Drug Saf; 2007; 30(3):247-64. PubMed ID: 17343431
[TBL] [Abstract][Full Text] [Related]
31. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015.
Engeland A; Bjørge T; Klungsøyr K; Hjellvik V; Skurtveit S; Furu K
Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):995-1004. PubMed ID: 29920833
[TBL] [Abstract][Full Text] [Related]
32. Common teratogenic medication exposures-a population-based study of pregnancies in the United States.
Wang Y; Smolinski NE; Thai TN; Sarayani A; Ewig C; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol MFM; 2024 Jan; 6(1):101245. PubMed ID: 38061552
[TBL] [Abstract][Full Text] [Related]
33. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
[TBL] [Abstract][Full Text] [Related]
34. First trimester topical tretinoin and congenital disorders.
Jick SS; Terris BZ; Jick H
Lancet; 1993 May; 341(8854):1181-2. PubMed ID: 8098078
[TBL] [Abstract][Full Text] [Related]
35. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Association Between Oral and Topical Terbinafine Use in Pregnancy and Risk of Major Malformations and Spontaneous Abortion.
Andersson NW; Thomsen SF; Andersen JT
JAMA Dermatol; 2020 Apr; 156(4):375-383. PubMed ID: 32129793
[TBL] [Abstract][Full Text] [Related]
37. Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy.
Andersson NW; Andersen JT
JAMA Dermatol; 2020 Mar; 156(3):303-311. PubMed ID: 31913405
[TBL] [Abstract][Full Text] [Related]
38. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity.
De Santis M; Straface G; Cavaliere A; Nobili E; Caruso A
Prev Med; 2007; 45(2-3):243-4. PubMed ID: 17640721
[No Abstract] [Full Text] [Related]
39. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations.
Drinkard CR; Shatin D; Clouse J
Pharmacoepidemiol Drug Saf; 2000 Dec; 9(7):549-56. PubMed ID: 11338912
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD).
Mikolajczyk RT; Kraut AA; Garbe E
Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):873-80. PubMed ID: 23733705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
